NASDAQ: NTBLNotable Labs Ltd Stock
$0.97+0.01 (+1.04%)
Updated Apr 26, 2024
NTBL Price
$0.97
Fair Value Price
-$0.02
Market Cap
$8.70M
52 Week Low
$0.83
52 Week High
$11.20
P/E
-0.28x
P/B
0.58x
P/S
20.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$310.00k
Earnings
-$11.15M
Gross Margin
36.5%
Operating Margin
-3,598.06%
Profit Margin
-3,598.1%
Debt to Equity
0.29
Operating Cash Flow
-$14M
Beta
0.95
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NTBL Overview
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NTBL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NTBL ($0.97) is overvalued by 4,535.42% relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NTBL ($0.97) is not significantly undervalued (4,535.42%) relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NTBL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NTBL due diligence checks available for Premium users.
Be the first to know about important NTBL news, forecast changes, insider trades & much more!
NTBL News
Valuation
NTBL fair value
Fair Value of NTBL stock based on Discounted Cash Flow (DCF)
Price
$0.97
Fair Value
-$0.02
Undervalued by
4,558.41%
NTBL ($0.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NTBL ($0.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NTBL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NTBL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.28x
Industry
14.88x
Market
41.14x
NTBL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
5.85x
NTBL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NTBL's financial health
Profit margin
Revenue
$310.0k
Net Income
-$6.6M
Profit Margin
-2,120.6%
NTBL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NTBL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.5M
Liabilities
$4.4M
Debt to equity
0.29
NTBL's short-term assets ($15.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NTBL's short-term assets ($15.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NTBL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NTBL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
$5.1M
Financing
$7.8M
NTBL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NTBL vs Biotech Stocks
Notable Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.